Trends in Immunotherapy

Commentary

Autoinflammatory disease, Nakajo-Nishimura syndrome and further perspective

Downloads

https://doi.org/10.24294/ti.v6.i2.1710
Furukawa, F. (2022). Autoinflammatory disease, Nakajo-Nishimura syndrome and further perspective. Trends in Immunotherapy, 6(2). https://doi.org/10.24294/ti.v6.i2.1710
Volume 6 Issue 2 (2022)

Copyright

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

License

Trends in Immunotherapy (TI)  publishes accepted manuscripts under Creative Commons Attribution 4.0 International (CC BY 4.0). Authors who submit their papers for publication by TI agree to have the CC BY 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for any purpose, including commercial use. As long as the author and original source are properly cited, anyone may copy, redistribute, reuse, and transform the content.

Authors

  • Fukumi Furukawa
    Takatsuki Red Cross Hospital Department of Forensic Medicine, Wakayama Medical University

  

Keywords:

Autoinflammatory Disease Nakajo-Nishimura Syndrome Proteasome Subunit β-Type 8 (PSMB8) Proteasome-associated Autoinflammatory Syndrome (PRAAS); Interferonopathy

References

  1. Inaba Y, Kunimoto K, Kanazawa N, Furukawa F. Antinuclear antibodies in Nakajo-Nishimura syndrome. A bridge with research on refractory autoimmune diseases. Trends in Immunotherapy 2018; 2: 1078. doi: 10.24294/ti.v2.i3.1078
  2. Inaba Y, Kunimoto K, Kanazawa N, Furukawa F. Effects of a humanized anti-human IL-6 receptor monoclonal antibody on Nakajo-Nishimura syndrome. Trends in Immunotherapy 2018; 2: 1051. doi: 10.24294/ti.v2.i3.1051
  3. Kondo N, Tanifuji O, Mochizuki T, et al. SAPHO syndrome in which certolizumab pegol was effective: A case report. Trends in Immunotherapy 2017; 1: 93–98. doi: 10.24294/ti.v1.i2.51
  4. Urano S, Abe J, Kikuchi H. Peristomal pyoderma gangrenosum successfully treated with cyclosporine. Trends in Immunotherapy 2022; 6(2): 4–8. doi: 10.24294/ti.v6.i2.1474
  5. Hashizume H, Kageyama R, Umayahara T, Morio T. A case of pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA) syndrome successfully treated with combination therapy of corticosteroids, cyclosporine, and colchicine. Trends in Immunotherapy 2018; 2: 719. doi: 10.24294/ti.v2.i2.719
  6. Kurokawa S, Tokura Y, Nguyen XN, et al. Acne fulminans coexisting with pyoderma gangrenosum-like eruptions and posterior scleritis. Journal of Dermatology 1996; 23(1): 37–41. doi: 10.1111/j.1346-8138.1996.tb03965.x
  7. Hu Y, Lin L, Cui P, et al. Clinical experience of combination therapy of infliximab and total glucosides of paeony for severe psoriasis with liver disorder history. Trends in Immunotherapy 2019; 3(2): 62–68. doi: 10.24294/ti.v3.i2.42
  8. Kanazawa N, Furukawa F. Autoinflammatory syndromes with a dermatological perspective. Journal of Dermatology 2007; 34(9): 601–618. doi: 10.1111/j.1346-8138.2007.00342.x
  9. Liu Y. Ramot Y, Torrelo A, et al. Mutations in proteasome subunit beta type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum 2012; 64(3): 895–907. doi: 10.1002/art.33368
  10. Kitamura A, Maekawa Y, Ueharae H, et al. A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans. Journal of Clinical Investigation 2011; 121(10): 4150–4160. doi: 10.1172/JCI58414
  11. Arima K, Kinoshita A, Mishima H, et al. Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proceedings of the National Academy of Sciences 2011; 108(36): 14914–14919. doi: 10.1073/pnas.1106015108
  12. Agarwal AK, Xing C, DeMartino GN, et al. PSMB8 encoding the beta5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome. American Journal of Human Genetics 2010; 87(6): 866–872. doi: 10.1016/j.ajhg.2010.10.031
  13. Kanazawa N. Nakajo-Nishimura syndrome: An autoinflammatory disorder showing pernio-like rashes and progressive partial lipodystrophy. Allergology International 2012; 61(2): 197–206. doi: 10.2332/allergolint.11-RAI-0416
  14. Kanazawa N, Kunimoto K, Ishii N, et al. Is CANDLE the best nomenclature? British Journal of Dermatology 2014; 171(3): 659–660. doi: 10.1111/bjd.12962
  15. Sarrabay G, Méchin D, Salhi A, et al. PSMB10, the last immunoproteasome gene missing for PRAAS. Journal of Allergy and Clinical Immunology 2020; 145(3): 1015–1017. doi: 10.1016/j.jaci.2019.11.024
  16. Poli MC, Ebstein F, Nicholaset SK, et al. Heterozygous truncating variants in POMP escape nonsense-mediated decay and cause a unique immune dysregulatory syndrome. American Journal of Human Genetics 2018; 102(6): 1126–1142.
  17. doi: 10.1016/j.ajhg.2018.04.010
  18. de Jesus AA, Brehm A, VanTries R, et al. Novel proteasome assembly chaperone mutations in PSMG2/PAC2 cause the autoinflammatory interferonopathy CANDLE/PRAAS4. Journal of Allergy and Clinical Immunology 2019; 143(5): 1939–1943. doi: 10.1016/j.jaci.2018.12.1012
  19. Brehm A, Liu Y, Sheikh A, et al. Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. Journal of Clinical Investigation 2015; 125(11): 4196–4211. doi: 10.1172/JCI81260
  20. Kanazawa N, Hemmi H, Kinjo N, et al. Heterozygous missense variant of the proteasome subunit β-type 9 causes neonatal-onset autoinflammation and immunodeficiency. Nature Communications 2021; 12: 6819. doi: 10.1038/s41467-021-27085-y
  21. Miyamoto T, Honda Y, Izawa K, et al. Assessment of type I interferon signatures in undifferentiated inflammatory diseases: A Japanese multicenter experience. Frontiers in Immunology 2022; 13: 905960. doi: 10.3389/fimmu.2022.905960